Vyvanse
Vyvanse Official FDA information, side effects and uses.
Shire's new ADHD medication now available - Pharmaceutical Business Review
Posted by Vyvanse (Vyvanse) on Sun, 05 Aug 2007 00:15:47 +0000
Shire eyes regenerative surgery market - Telegraph.co.uk
Shire Reports $1.81 Billion Loss After Acquisition (Update1) - Bloomberg
UPDATE 1-Shire Q2 earnings rise, ups 2007 revenue forecast - Reuters.uk
Ahead of the Bell: Shire Drops - Forbes
Posted by Vyvanse (Vyvanse) on Sun, 05 Aug 2007 00:15:47 +0000
| Shire's new ADHD medication now available Pharmaceutical Business Review - By Staff Writer Shire says Vyvanse, its once-daily medication approved to treat the symptoms of attention deficit hyperactivity disorder, is now available ... |
Shire eyes regenerative surgery market - Telegraph.co.uk
| Shire eyes regenerative surgery market Telegraph.co.uk, United Kingdom - The company said the launch of Vyvanse, its latest product for attention deficit, had exceeded expectations. Vyvanse is the first slow-release ADHD product ... |
Shire Reports $1.81 Billion Loss After Acquisition (Update1) - Bloomberg
| Shire Reports $1.81 Billion Loss After Acquisition (Update1) Bloomberg - Shire in April paid $2.6 billion for partner New River to gain full rights for Vyvanse, a replacement for its top-selling attention deficit medicine ... |
UPDATE 1-Shire Q2 earnings rise, ups 2007 revenue forecast - Reuters.uk
| UPDATE 1-Shire Q2 earnings rise, ups 2007 revenue forecast Reuters.uk, UK - Shire is now hoping to switch patients onto Vyvanse, a next-generation ADHD drug which it launched earlier this month, before Adderall XR faces generic ... |
Ahead of the Bell: Shire Drops - Forbes
| Ahead of the Bell: Shire Drops Forbes, NY - Shire (nasdaq: SHPGY - news - people ) makes both Vyvanse and Adderall. Analyst Alistair Campbell said that Vyvanse sales will miss Wall Street expectations ... |
